Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04206319 trial: what clinicians have said so far
Radium-223 in Biochemically Recurrent Prostate Cancer
- NCT04206319 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04206319 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04206319 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Biochemical Recurrent Prostate Cancer
- Interventions
- Radium-223; 18F Sodium Fluoride
- Arms
- 1 · Experimental
- Enrollment
- 19
- Primary outcomes
- changes in immune cell populations
- Sponsor
- National Cancer Institute (NCI)
- Start
- Sep 22, 2020
- Primary completion
- Feb 10, 2026
- Results posted
- No
- Registry record
- NCT04206319 · updated Mar 16, 2026